Last updated: March 26, 2026
What is the Product?
NDC 64980-0668 corresponds to Regen-Cel (regorafinib tablets), a kinase inhibitor approved for the treatment of various cancers, primarily colorectal cancer and gastrointestinal stromal tumors (GIST). Regorafinib functions as an oral multikinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and other pathways involved in tumor angiogenesis and proliferation.
Market Size and Demand
Current Market Landscape
The global oncology drug market for tyrosine kinase inhibitors (TKIs) was valued at approximately USD 17.4 billion in 2022, with expected compound annual growth rate (CAGR) of 7% through 2030. Regorafinib, specific to GIST and colorectal cancers, accounts for a subset of this market, estimated at USD 0.8 billion in 2022.
Key Market Drivers
-
Incidence Rates:
- Colorectal cancer accounts for over 1.9 million new cases annually worldwide (WHO, 2022).
- GIST incidence: approximately 10-15 cases per million annually.
-
Treatment Landscape:
- Regorafinib is used after failure of first-line therapies.
- FDA approval for metastatic colorectal cancer (2012), GIST (2013).
- Increasing usage due to improved outcomes compared to alternative therapies.
-
Competitive Dynamics:
- Competes with sunitinib, pazopanib, and other multi-kinase inhibitors.
- Recently facing competition from novel agents like cabozantinib and larotrectinib.
Market Penetration
- In 2022, regorafinib held approximately 45% share within the specified niche.
- Projected growth depends on expansion into earlier treatment lines and additional indications.
Price Trends and Projections
Current Pricing Data
- The average wholesale price (AWP) for a 28-tablet pack (40 mg) is approximately USD 16,000.
- Estimated annual treatment cost per patient: USD 192,000 (assuming daily dosing of 160 mg).
- Insurance coverage varies; many payers negotiate discounts reducing the net cost.
Factors Impacting Price Dynamics
Price Projections (2023-2028)
| Year |
Estimated Price per Pack |
Notes |
| 2023 |
USD 16,000 |
Current price; no significant change expected. |
| 2024 |
USD 15,500 |
Slight decrease due to market adjustments. |
| 2025 |
USD 14,500 |
Price pressure from increasing competition. |
| 2026 |
USD 8,000 |
Potential entry of generics; sharp decline expected. |
| 2027 |
USD 7,000 |
Generic market dominance stabilizes prices. |
| 2028 |
USD 6,500 |
Continued price erosion, slight recovery possible. |
Regulatory and Market Entry Considerations
- Patent expiration in the US and EU will trigger generic development processes.
- Biosimilar debate less relevant as the drug is small-molecule.
- Manufacturers might pursue patent extensions or regulatory exclusivity to extend market life.
Strategic Recommendations
- R&D investments should focus on combination therapies or expanded indications before patent expiry.
- Companies should plan for price erosion post-2026 and consider licensing or alliances for late-stage generic market entry.
- Monitored regulatory policies on drug pricing can significantly affect profitability.
Key Takeaways
- The current market is approximately USD 0.8 billion, growing steadily with unmet needs.
- Pricing at USD 16,000 per pack is stable, with significant declines expected post-2026 upon patent expiry.
- Competition from generics and biosimilars will reshape the landscape.
- Future revenue depends on market penetration, approval of additional indications, and patent strategies.
FAQs
-
When will generic versions of regorafinib likely enter the market?
Patent expiration is expected around 2026-2028, after which generics will enter.
-
How does regulatory pressure influence pricing trends?
Authorities in key markets are increasingly pressing for price negotiations, which can cap prices and reduce profit margins.
-
What are the main competitors to regorafinib?
Sunitinib, pazopanib, cabozantinib, and larotrectinib.
-
What patient populations are most impacted by price changes?
Patients with metastatic colorectal cancer and GISTs, primarily in high-income markets with insurance coverage.
-
How does efficacy influence market demand?
Higher efficacy and safety profiles increase adoption and brand retention, delaying the impact of generics.
Sources:
[1] WHO. (2022). Global Cancer Statistics. World Health Organization.
[2] IMS Health. (2022). Oncology Market Report.
(Note: Actual URLs or DOI links are omitted for brevity).
